Updated 02:01 GMT, 16 Nov 2026 SPX 7,561.67 -0.40% NDX 27,943.74 -1.22% VIX 19.30 +3.21% GOLD 3,876.40 -0.25% CL 88.33 -0.26% BTC 64,613.34 +0.76%
NAS100 27,944 −1.22% S&P 7,562 −0.40% GOLD $3,876 −0.25% BTC $64,613 +0.76% VIX 19.30 +3.21% latest tape · as of 02:01 UTC
The Screen · Healthcare · Biotechnology

Arrowhead Pharmaceuticals Inc logoArrowhead Pharmaceuticals Inc

ARWR · NASDAQ · USD · Market cap $8.1B · 711 employees

Arrowhead Pharmaceuticals, Inc.

FAIL · Does not pass the screen
47.78 USD

Price as of 13 Nov 2026Daily close, not a live quote

Screened 2026-11-13 · the tape above runs as of 02:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price47.78 USD at the 13 Nov 2026 close
  • Fair valueUnder review: our model's value is 2.23x the price, above our 2.00x limit.
  • Our regime readDistribution, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans slightly to calls (put/call 0.80)
  • Last reviewed13 Nov 2026 (3 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: range not available (screen dated 2026-11-13).

Current read
Distribution ?
Screened · screened 2026-11-13
  • Trend Distribution
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.80, read 2026-11-13
  • Ethical does not pass the values gate
Price47.78 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-11-12Read Distribution49.36-3.2% to today ✓Markdown gives way to Distribution after a 16% slide in 3 weeks
2026-10-20Read Markdown58.50-18.3% to today ✓Distribution gives way to Markdown after a 15% slide in 4 weeks
2026-09-24Read Distribution68.79-30.5% to today ✓Markup gives way to Distribution after a 20% slide in 5 weeks
2026-08-22Read Markup85.59-44.2% to today Distribution gives way to Markup after a 15% rise in 7 weeks

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its distribution label.

Arrowhead Pharmaceuticals Inc holds its Distribution at $47.78. Elevated stress, defensive posture warranted, held for 4 days.

As held on the ledger · 2026-11-13
PhaseDistribution · caution
Quantitative stateElevated stress, defensive posture warranted, held for 4 days
Price at the screen$47.78
ValuationN/A trailing · -11.54 forward price to earnings
Values screenFAIL · score 70.0
Beta1.37
The Workings

Five Screens, Shown in Full

Does not pass. Interest-bearing securities

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 26.44% Below 33% Interest-bearing debt is just 26.4% of its assets, well under the one-third ceiling: it does not run on borrowed money. Pass
Interest-bearing cash 59.96% Below 33% Interest-bearing cash and securities are 60.0% of assets, above the one-third limit. Fail
Receivables 6.90% Below 49% Money owed to the company is 6.9% of assets, under the 49% limit. Pass
Revenue purity 4.50% Below 5% Only 4.5% of revenue comes from non-compliant sources, under the 5% line. Pass

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

Arrowhead Pharmaceuticals's business is fine, but its cash and interest-bearing securities are about 60% of its assets, well over the ~33% line, so it does not pass on the financial screens.

Read as at 2026-11-14. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when ARWR's ethical verdict changes

Today ARWR does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Fair value under review. Our model's value is 2.23x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.

How a fair value is estimated: discounted cash flow (DCF).

The Street's Range
74.00Street low 106.50Street average 126.00Street high 47.78Price

Third-party analyst targets: 14 covering, consensus Strong Buy. The average target sits +123% from the screen price.

Price History & Projections

Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-13 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Biotech Hopes Clash With Shrinking Revenue

Picture a lab racing to turn early drug trials into real medicines while sales collapse. Arrowhead develops RNA based treatments for stubborn diseases, yet its latest numbers show revenue down 86 percent and a 48 percent loss margin. Analysts still cluster around a 97 dollar target, but our reading sees no edge worth taking.

The business carries a weak moat, negative return on equity of 42 percent, and a forward multiple that reflects deep losses rather than growth. Even with an ethical pass and a listed margin of safety to 97 dollars, the opportunity rating stays at none because the underlying metrics point to execution risk, not value.

Clinical setbacks remain the norm in this field, and a single failed Phase 3 study can wipe out years of work. Currency moves or funding squeezes add further pressure on a company already burning cash. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E-11.5x
EPS, trailing-2.28
EPS, forward-4.98
Revenue growth+171.0%growing very fast
Profit margin-47.8%currently unprofitable
Return on equity-55.2%not currently earning a positive return on equity
FCF yield-0.60%
Debt to equity2.96heavy leverage: higher risk if revenue softens
Current ratio5.90comfortably covers its short-term bills
Beta1.37moves a little more than the market
Short interest, float0.11%
52-week range37.06 - 95.49
MoatWEAK
Market cap$8.1B
Employees711

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

ARWR trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-12 Distribution · changed $49.36 +0.7% Entry 20

The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 0.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 318%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (12 analysts) rates it buy, with a mean price target of $89. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-11 Markdown $49.00 -0.5% Entry 19

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 318%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (12 analysts) rates it buy, with a mean price target of $89. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-10 Markdown $49.24 -15.3% Entry 18

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 15.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 318%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (12 analysts) rates it buy, with a mean price target of $89. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-09 Markdown $58.16 +0.0% Entry 17

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 318%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (12 analysts) rates it buy, with a mean price target of $89. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-08 Markdown $58.16 +0.0% Entry 16

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 17% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 318%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (12 analysts) rates it buy, with a mean price target of $89. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-07 Markdown $58.16 +1.2% Entry 15

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 17% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 318%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (12 analysts) rates it buy, with a mean price target of $89. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-06 Markdown $57.46 -6.8% Entry 14

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 6.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 17% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 318%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (12 analysts) rates it buy, with a mean price target of $89. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-05 Markdown $61.65 +2.9% Entry 13

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 2.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 17% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 318%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (12 analysts) rates it buy, with a mean price target of $89. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-03 Markdown $59.90 +2.6% Entry 12

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 2.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 17% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 318%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (12 analysts) rates it buy, with a mean price target of $89.

2026-10-27 Markdown $58.36 -0.2% Entry 11

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 17% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 318%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (12 analysts) rates it buy, with a mean price target of $89.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on ARWR

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in ARWR's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $77.74 -8.8% · $912 -8.8%
2 months $65.14 +8.9% · $1,089 +8.9%
3 months $55.01 +28.9% · $1,289 +28.9%
6 months $70.82 +0.1% · $1,001 +0.1%
1 year $16.97 +317.9% · $4,179 +317.9%
2 years $24.51 +189.3% · $2,893 +189.3%
3 years $35.32 +100.8% · $2,008 +100.8%
5 years $88.71 -20.1% · $799 -20.1%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever ARWR does next, these words stay.

Arrowhead Pharmaceuticals Inc · ARWR · Distribution · $47.78
Recorded 2026-11-13 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.